Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose ladostigil for prevention of progression from mild cognitive impairment to Alzheimer's disease
2011-004187-30Phase 2Completed
- Sponsor
- Avraham Pharmaceuticals Ltd.
- Start
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Mild Cognitive Impairment (MCI) and Alzheimer's disease (AD) comparing Ladostigil 10 mg q.d with Placebo q.d (2 arms). Primary endpoint: Progression from mild cognitive impairment to Alzheimer's disease. Started Nov 2011; status: completed.
02
Drugs
ladostigil
03
Conditions
Mild Cognitive Impairment (MCI)Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2011-004187-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004187-30.